-
Mashup Score: 18
Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
RT @MAWildgust: Excited to share the US FDA approval for RYBREVANT based on the PAPILLION study! #MyCompany https://t.co/Q06dQz4SLl https:…
-
-
Mashup Score: 8
/PRNewswire/ — Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
At @JNJInnovMed, we continue to advance the science of #LungCancer. We’ve submitted our third application to the U.S. FDA in four months for the treatment of this disease. See how we're advancing innovative targeted therapies for patients: https://t.co/brqxieKZCC #MyCompany https://t.co/Rmp5OwYry0
-
-
Mashup Score: 38
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
Supported by data from the Phase 3 MARIPOSA-2 study, #MyCompany submitted a sBLA to the U.S. FDA for the treatment of patients with locally advanced or metastatic EGFRm NSCLC after treatment with osimertinib. https://t.co/dzyUrMUFGc #MyCompany #Innovation #PrecisionMedicine https://t.co/x5aGsR8yRu
-
-
Mashup Score: 5
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The 5 year survival rate for EGFR-mutated non-small cell lung cancer is less than 20%. [tag] @JNJInnovMed is committed to changing this statistic. Learn about our topline results from the pivotal Phase 3 MARIPOSA study in patients with EGFR-mutated #NSCLC: https://t.co/fqc5ZYkmHO https://t.co/dTx2RXoJrO
-
-
Mashup Score: 2
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study…
Source: www.prnewswire.comCategories: Latest Headlines, Oncologists1Tweet-
RT @Exon20Group: Congrats! Ph 3 MARIPOSA-2 Study Met Dual Primary Endpoint https://t.co/IeDbgB1C9s
-
-
Mashup Score: 8
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study…
Source: www.prnewswire.comCategories: Latest Headlines, Oncologists1Tweet-
Hope can feel hard to hang onto for patients with EGFR-mutated lung cancer. That's why @JanssenGlobal is studying combination-based regimens across multiple clinical trials for this patient population. Check out our latest Phase 3 topline results: https://t.co/gvKvIiX07p https://t.co/41u9U9XCqy
-
-
Mashup Score: 3ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology - ILCN.org (ILCN/WCLC) - 1 year(s) ago
In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field.
Source: ILCN.org (ILCN/WCLC)Categories: Latest Headlines, Oncologists1Tweet-
RT @DrewMoghanaki: This man is a mensch! He truly cares about others as much as anyone I’ve ever met. https://t.co/d4pFxf2EeG https://t.co/…
-
-
Mashup Score: 1Building Equitable Access to Next-Generation Sequencing and Targeted Therapies for All Patients With Lung Cancer - 2 year(s) ago
The cancer research landscape looked vastly different when I began my career almost 15 years ago. As just one example, when I graduated from medical school, tyrosine kinase inhibitors (TKIs) were approved for the treatment of non-small cell lung cancer (NSCLC), but the fact that specific genetic mut
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeted therapy has transformed lung cancer treatment, but the right target must be identified for each patient. Genetic testing using next-generation sequencing is a critical step in finding the best therapeutic option for patients with lung cancer. https://t.co/kU8XkWp1xu
-
-
Mashup Score: 4An integrated approach combining prevention, interception and treatment to tackle lung cancer - 2 year(s) ago
Johnson & Johnson’s integrated approach to tackling lung cancer hopes to save lives and gather lessons for other cancer types.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
This #WorldLungCancerDay, I am proud to work for a company committed to addressing the continued unmet needs of patients with lung cancer. #MyCompany https://t.co/wmfyQbKK1O
-
My team at @JNJInnovMed is sharing data at #ELCC24, reinforcing the potential of our innovative targeted therapy. These latest findings demonstrate our commitment to advancing the science of #LungCancer through our robust clinical program: https://t.co/kUzm3voz2L https://t.co/HfaxlhWu8A